News
IPSC
1.670
-1.18%
-0.020
Weekly Report: what happened at IPSC last week (0914-0918)?
Weekly Report · 6d ago
Weekly Report: what happened at IPSC last week (0907-0911)?
Weekly Report · 09/14 09:16
Century Therapeutics Appoints IECURE CEO Joseph Truitt To Board As CNTY-813 Nears IND Filing
NASDAQ · 09/10 07:13
Century Therapeutics Adds Director, Advances Cell Therapy Pipeline
TipRanks · 09/09 20:31
Press Release: Century Therapeutics Appoints Joseph Truitt to Board of Directors
Dow Jones · 09/09 20:05
*Century Therapeutics Appoints Joseph Truitt to Bd of Directors
Dow Jones · 09/09 20:05
Weekly Report: what happened at IPSC last week (0831-0904)?
Weekly Report · 09/07 09:15
Weekly Report: what happened at IPSC last week (0824-0828)?
Weekly Report · 08/31 09:16
Weekly Report: what happened at IPSC last week (0817-0821)?
Weekly Report · 08/24 09:16
Century Therapeutics (IPSC) Gets a Buy from Mizuho Securities
TipRanks · 08/17 16:15
Weekly Report: what happened at IPSC last week (0810-0814)?
Weekly Report · 08/17 09:16
Phil Nadeau Initiates Buy on Century Therapeutics, Citing Promising T1D Program, Advancing Pipeline, and Strong Cash Runway
TipRanks · 08/13 14:36
Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC), Talphera (TLPH) and Cognition Therapeutics (CGTX)
TipRanks · 08/13 10:30
Clear Street Sticks to Its Buy Rating for Century Therapeutics (IPSC)
TipRanks · 08/13 07:18
Century Advances CNTY-813; IND Submission On Track For Q4 2026
NASDAQ · 08/12 18:02
Century Therapeutics Reports Q2 Results, Pipeline Advancements
TipRanks · 08/12 12:48
Century Therapeutics Q2 EPS $(0.17) Misses $(0.14) Estimate
Benzinga · 08/12 12:05
Century Therapeutics GAAP EPS of -$0.17 misses by $0.05
Seeking Alpha · 08/12 12:03
*Century Therapeutics 2Q Loss/Shr 17c >IPSC
Dow Jones · 08/12 12:01
*Century Therapeutics 2Q Rev $0.00 >IPSC
Dow Jones · 08/12 12:01
More
Webull provides a variety of real-time IPSC stock news. You can receive the latest news about Century Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About IPSC
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.